Tweets
PRE-CLINICAL RA: What do you need to better manage pre-clinical (at-risk) Rheumatoid arthritis Patients? Rheumatologists vote here >>https://t.co/lt38vJMEIA
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
RheumNow’s new Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Posters addressing vasculitis, AxSpa and nrAxSpa, and PMR now available.
https://t.co/38foNET3j4 https://t.co/8CjXwzyGab
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
In pts seeking care for MSK pain cannot assume that improving pain/function will result in improved depression, but substantial improvements are required to effect anxiety. Study of 11 236 Ortho pts in JAMA https://t.co/5vvoPs31GU https://t.co/gEwZNW35xB
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
Study of FDA review times for New Indication Approvals of Drugs and Biologics (2017 - 2019) finds FDA approved 107 drugs for 146 new indications [99 small molecules (68%) & 47 biologics (32%)]. Median regulatory review time was 6 mos (IQR, 6-10) https://t.co/3P6T4R4FCF https://t.co/avl65W3kvr
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
UK MHRA reminder that NSAIDs are:
- contraindicated in the 3rd trimester of pregnancy (>28wks)
- >20 wks - assoc w/ increased risk of oligohydramnios & fetal renal dysfunction
MDs should avoid NSAIDs in pregnancy after wk 20 https://t.co/u3fTnuoF17 https://t.co/b2b5XThe1i
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
Predictors of Cardiovascular Events in ANCA-Associated Vasculitis
A large, retrospective, multinational study of patients with ANCA-AAV shows they may be at risk for CVEs.
https://t.co/k9XPolEXKc https://t.co/0nxai3Eqe2
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
Check SSc-ILD Patients on Nintedinib for Malnutrition
During nintedanib treatment for interstitial lung disease associated with SSc-ILD, clinicians prescribing the drug should be watchful for an unusual, indirect side effect, trial data suggested.
https://t.co/5Q3xCwLvPa https://t.co/mGD3DCYZR0
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
RheumNow LIVE VOTE Survey:
What do you need to better manage pre-clinical (at-risk) Rheumatoid arthritis? Please vote here >>https://t.co/lt38vJMEIA
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
Comprehensive, full-read overview of SLE treatment with Tyk2 vs JAK inhibitors https://t.co/KjLEYGfxAY https://t.co/btvoBQjboi
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
2022 of fibromyalgia Year in review discusses possible causes (inflammation, gut dysbiosis, neuroinflammation), new Rx (kinin antagonists, neurostimulation, mind-body Rx; but more needed on ketamine, vitamin D, and hormonal therapy https://t.co/IovNztH1kP https://t.co/fEVjO6ZW67
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
Mirikizumab, an anti-IL-23 MAb, shown to be effective in phase 2 trial in ulcerative colitis. 1281 Pts: mirikizumab > placebo group w/ remission at wk 12 (24% vs 13%, P<0.001) & after re-randomization & maintenance @wk 40l (50% vs 25%, P<0.001) https://t.co/9ZPsRCDhJc https://t.co/jrJvzAhyWY
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
Metanalysis of JAK inhib in Alopecia Areata: 7 RCTs &1710 patients shows JAK inhibitors yielded > 50% hair regrowth (OR 5.28) or > 90% improvement (OR 8.15) vs PBO. Oral JAK inhibitors were better than topical (latter = PBO). https://t.co/J9kGh89aEi https://t.co/QbMY1m4NQe
Links:
Dr. John Cush @RheumNow ( View Tweet )
2 years 8 months ago
